Lung Cancer Update

Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.

Lung Cancer Update is a science podcast hosted by Dr. Neil Love, with 61 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Dr. Neil Love hosts Lung Cancer Update, a science show with 61 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #51

  Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

  Aug 7, 20261h 59mS24

  Featuring perspectives from Dr Anne Chiang, Dr Apar Kishor Ganti, Dr Luis Paz-Ares and Dr Misty Dawn Shields, moderated by Dr Shields, including the following topics: Introduction (0:00) Optimizing First-Line and Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (SCLC) — Dr Shields (2:17) Management of Relapsed/Refractory SCLC — Dr Paz-Ares (33:24) Ongoing Investigation and Potential Role of Antibody-Drug Conjugates in SCLC — Dr Chiang (1:02:28) Management of Limited-Stage SCLC — Dr Ganti (1:31:54) CME information and select publications

  ListenShow Notes
• 

  Episode #50

  Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR

  Aug 4, 202659 minS24

  Featuring perspectives from Dr John V Heymach and Dr Maurice Pérol, including the following topics: Introduction: Relative Impact of Targeted Treatment (00:00) HER2 Alterations (8:04) KRAS Mutations (24:25) MET Overexpression (30:34) ALK Fusions (32:34) ROS1 Fusions (42:36) RET Fusions (52:00) CME information and select publications

  ListenShow Notes
• 

  Episode #48

  HER2-Altered Non-Small Cell Lung Cancer — 5-Minute Journal Club: Microlearning Activity 2

  Jul 30, 202617 minS24

  Featuring perspectives from Dr Joshua K Sabari, including the following topics: Heymach JV et al. Zongertinib in previously treated HER2-mutant non-small cell lung cancer. N Engl J Med 2025;392(23):2321-33. (0:00) Popat S et al. Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG-1. ESMO 2025;Abstract LBA74. (5:25) Le X et al. Sevabertinib in advanced HER2-mutant non-small cell lung cancer. N Engl J Med 2025;393(18):1819-32. (12:37) CME information and select publications

  ListenShow Notes
• 

  Episode #46

  HER2-Altered Non-Small Cell Lung Cancer — Rapid Case Review

  Jul 14, 202628 minS24

  Featuring an interview with Dr Mark Jeng and Dr Joshua K Sabari, including the following topics: Case: A woman in her late 90s with recurrent HER2-mutant metastatic non-small cell lung cancer (NSCLC) receives third-line zongertinib (0:00) Case: A woman in her early 60s with multiregimen-recurrent HER2-mutant metastatic NSCLC experiences a response to zongertinib (8:07) Case: A man in his mid 80s experiences metastatic recurrence after resection of PD-L1-positive, HER2-mutant metastatic NSCLC (17:50) CME information and select publications

  ListenShow Notes
• 

  Episode #45

  Nonmetastatic Non-Small Cell Lung Cancer — An Interview with Dr Jamie E Chaft

  Jul 11, 20261 hourS24

  Featuring an interview with Dr Jamie E Chaft, including the following topics: Case: A man in his early 70s with a 40 to 50 pack-year history of smoking and cT2bN1 squamous cell carcinoma of the lung with PD-L1 60% treated with induction therapy and surgery (00:00) Available clinical data with immunotherapy in the neoadjuvant, perioperative and adjuvant settings (07:45) Factors in the selection of adjuvant immunotherapy, including circulating tumor DNA (11:39) Evolving approaches to management, including systemic therapy, surgery and radiation therapy techniques (19:28) Case: A woman in her early 60s with nonmetastatic non-small cell lung cancer (NSCLC) and an EGFR exon 19 deletion who is enrolled in the NeoADAURA study (24:03) Importance of clinical trials in the adjuvant setting (33:02) Data surrounding treatment in the neoadjuvant setting; key implications of the NeoADAURA study (35:41) Case: A man in his late 60s with a history of smoking and Stage III T4N3 NSCLC not otherwise specified with low PD-L1 expression, high tumor mutation burden, microsatellite stability and an STK11 mutation (41:34) Selecting patients for the NeoADAURA study treatment approach; deciding between chemoimmunotherapy and chemoradiation therapy (51:01) CME information and select publications

  ListenShow Notes

Recent guests on Lung Cancer Update. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.